Nausea, diarrhea, vomiting and constipation are common side effects in branded Zepbound studies. Knowing what to try at home and when to contact your clinician helps you respond to symptoms. This guide separates those branded-drug findings from practical care questions for people prescribed compounded tirzepatide. LABEL
Research checked: October 19, 2026.
What are the most common tirzepatide side effects?
Digestive symptoms lead the list in the branded Zepbound label. Other reported effects include stomach pain, indigestion, fatigue, burping, reflux, injection-site reactions and hair loss. LABEL
The table below is a dated reading of Zepbound label section 6.1, checked October 19, 2026. These are percentages of participants in pooled branded-drug Studies 1 and 2, not predicted rates for people using compounded tirzepatide. Trial rates may differ from everyday practice. LABEL
| Side effect | Placebo (958 people) | Zepbound 5 mg (630 people) | Zepbound 10 mg (948 people) | Zepbound 15 mg (941 people) |
|---|---|---|---|---|
| Nausea | 8% | 25% | 29% | 28% |
| Diarrhea | 8% | 19% | 21% | 23% |
| Vomiting | 2% | 8% | 11% | 13% |
| Constipation | 5% | 17% | 14% | 11% |
These dose groups describe the study. They are not doses to choose from or a reason to change your prescription.
What can help with tirzepatide nausea?
Try smaller portions, eat slowly and stop when you feel full. Bland, lower-fat food and small sips of fluid may be easier to tolerate. These suggestions come from an expert consensus on approved GLP-1 medicines, not a trial of Sprout’s compounded preparation. GI
Write down when nausea starts, what you ate and whether it followed a dose change. If symptoms persist, contact your prescriber rather than increasing, reducing or splitting doses yourself. Ask before adding an anti-nausea medicine. GI
What can help with tirzepatide constipation?
Adequate fluids, fiber and movement are the consensus starting points. Ask your clinician what fits your needs, particularly if you have a fluid restriction. If that does not help, ask whether a bowel medicine is appropriate; this guide does not select a laxative or dose. GI
Do not assume persistent stomach pain is just constipation. Severe or persistent symptoms need medical assessment, not repeated home remedies. LABEL
Which symptoms need urgent help?
The following actions summarize the branded Zepbound Medication Guide and warnings MG. They are not a complete safety assessment for a compounded prescription. LABEL
| What you notice | What to do |
|---|---|
| Trouble breathing or swallowing; swelling of the face, lips, tongue or throat | Seek emergency medical help. The label says to stop Zepbound for a serious allergic reaction. |
| Severe stomach pain that does not go away, with or without vomiting, possibly reaching the back | Stop the medicine and seek medical help right away; the branded label warns about pancreatitis. |
| Nausea, vomiting or diarrhea that does not go away | Contact your clinician promptly; fluid loss can contribute to kidney injury. |
| Upper stomach pain, fever, yellow skin or eyes, or clay-colored stools | Contact a clinician right away for possible gallbladder problems. |
For severe symptoms, do not wait for a routine portal reply. Tell the medical team the exact product and dose on your prescription label.
How long do side effects last?
In branded Zepbound studies, most nausea, vomiting and diarrhea occurred during dose escalation and decreased over time. That does not set a deadline for your symptoms or mean you should tolerate severe symptoms. Constipation may need its own care plan. LABEL GI
Before treatment, discuss a personal or family history of medullary thyroid cancer, MEN 2, serious allergic reactions, severe stomach-emptying problems, pregnancy and your other medicines. The branded label includes a boxed thyroid-tumor warning based on animal findings; the human risk is unknown. Tell the team about planned anesthesia or deep sedation, too. LABEL
Use our food guide for meal ideas, and the dose-label guide to prepare questions about your directions.
How does Sprout fit into my care decision?
Sprout offers online clinician review for compounded tirzepatide. Use the intake to share your medical history and questions; a clinician decides whether treatment is appropriate and sets the prescription. Completing an intake does not guarantee a prescription. OFFER
Compounded drugs are not FDA-approved. The branded-drug data and general GLP-1 guidance cited here are not evidence of the same safety or results for Sprout’s compounded preparation. FDA
The 12-month compounded tirzepatide plan is $149/mo equivalent, billed $1,788 upfront. Other plan lengths are available. These are the offer figures verified October 18, 2026, not a monthly-payment arrangement. See the plan-cost guide for the other billing periods, and read the cancellation and refund policy before purchasing. OFFER
For the care process, read the compounded tirzepatide guide. For directions on your prescription, use the dose-label guide to prepare questions for your pharmacist, not to select a dose.
Frequently asked questions
Does everyone get nausea?
No. Nausea was reported by some, not all, participants in branded Zepbound studies. Those rates do not predict your experience with compounded tirzepatide. [LABEL](https://pi.lilly.com/us/zepbound-uspi.pdf)
Should I increase my dose if I have no side effects?
No. Follow your prescription. The branded label considers both treatment response and tolerability; symptoms alone are not a dosing rule. [LABEL](https://pi.lilly.com/us/zepbound-uspi.pdf)
Can I treat persistent vomiting at home?
Contact your clinician promptly. The branded label warns that ongoing vomiting or diarrhea can cause dehydration and contribute to kidney injury. [LABEL](https://pi.lilly.com/us/zepbound-uspi.pdf)
Next step
See if you qualify. This starts an intake, not a prescription or a dose recommendation.
Sources and method
This educational guide uses the branded Zepbound label for drug-specific safety facts. PubMed-indexed studies or consensus guidance are identified by design and population; none tested Sprout compounded products. Tables and appointment checklists are editorial summaries, not personalized medical instructions.
- Zepbound US prescribing information and Medication Guide — Local zepbound-label.pdf, retrieved October 18, 2026; August 2026 revision; read October 19, 2026. Branded Zepbound only; not a study of Sprout compounded preparations.
- Gorgojo-Martínez et al. Clinical recommendations to manage gastrointestinal adverse events (2022) — PubMed indexed record verified; full text PMC9821052 retrieved through Europe PMC XML, HTTP 200, October 19, 2026. Expert consensus for approved GLP-1 receptor agonist therapy, not a compounded tirzepatide trial.
- FDA compounding questions and answers — Inherited verified wave-1 source, HTTP 200 October 18, 2026; regulatory status only. Approval distinction, not side-effect evidence.
- Sprout current offer and clinician-review process — Founder-approved brief and prices-verified.json; website origin/main SHA 4a57071a8005291dbf7d8ee8a8b719cfeae1f837, October 18, 2026. Dated offer snapshot; no pharmacy certification or availability guarantee.
-
Sprout cancellation and refund policy — Verified wave-1 policy source October 18, 2026; linked without paraphrased refund promises. Reader should review applicable terms before purchase.
-
Zepbound FDA-approved Medication Guide — Direct manufacturer PDF GET, HTTP 200, October 19, 2026; warning symptoms checked against PDF text. Branded Zepbound patient labeling; not a compounded-product safety study.